Ken Griffin Logic Bio Therapeutics, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.67 $33,618 - $77,669	115,925 New	115,925 $32,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.53 $9,570 - $19,705	4,350 Added 30.53%	18,600 $42,000
Q2 2021 Aug 16, 2021	BUY	$4.03 - $7.57 $57,427 - $107,872	14,250 New	14,250 $63,000
Q1 2021 May 17, 2021	SELL	$6.8 - $9.16 $220,524 - $297,058	-32,430 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.29 - $9.1 $171,554 - $295,113	32,430 New	32,430 $248,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.